Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

NasdaqCM - Nasdaq Real Time Price USD

PDS Biotechnology Corporation (PDSB)

Compare

1.2300

-0.1100

(-8.21%)

At close: March 7 at 4:00:01 PM EST

1.2400

+0.01

+(0.81%)

After hours: March 7 at 7:58:45 PM EST

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

First-ever HPV16-positive head and neck cancer Phase 3 clinical trialPRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the initiation of the VERSATILE-003 Phase 3 clinical trial. The trial is now open to patient enrollment. “We are thrilled to share that the first trial site has been initiated

GlobeNewswire 2 days ago

PDSB
-8.21%
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$11 Million Upfront with up to an Additional $11 Million of Aggregate Gross Proceeds Upon the Cash Exercise in Full of the WarrantsPRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced it has entered into securities purchase agreements with new and existing healthcare focused institutional investors

GlobeNewswire 10 days ago

PDSB
-8.21%
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months Significant tumor shrinkage with confirmed objective response rate (ORR) of 75% in HPV16-positive immune checkpoint

GlobeNewswire 11 days ago

PDSB
-8.21%
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells (circulating tumor DNA/ctDNA) vs. CRT alone 100% of patients with locally advanced HPV16 cervical cancer treated with Versamune® HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients

GlobeNewswire 13 days ago

PDSB
-8.21%
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat at the B. Riley Securities Precision Oncology & Radiopharma Conference 2025 taking place on Friday, February 28, 2025. Details of

GlobeNewswire 17 days ago

PDSB
-8.21%
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

FDA-cleared amended trial design; First site initiation expected Q1 2025PRINCETON, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune® HPV plus pembrolizumab for first-line treatment of recurrent and/or metastatic (R

GlobeNewswire last month

PDSB
-8.21%
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment

GlobeNewswire 3 months ago

PDSB
-8.21%
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiationPRINCETON, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced a Key Opinion Leader (“KOL”) event to discu

GlobeNewswire 3 months ago

PDSB
-8.21%
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 3 months ago

PDSB
-8.21%
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

PDS Biotechnology Corp (PDSB) reports a solid cash position amid increased R&D expenses and promising clinical trial updates.

GuruFocus.com 3 months ago

PDSB
-8.21%
MRUS
PDS Biotechnology: Q3 Earnings Snapshot

EAST PRINCETON, N.J. (AP) — PDS Biotechnology Corporation (PDSB) on Thursday reported a loss of $10.7 million in its third quarter. The East Princeton, New Jersey-based company said it had a loss of 29 cents per share. The results matched Wall Street expectations.

Associated Press Finance 3 months ago

PDSB
-8.21%
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

Conference call and webcast today at 8:30 a.m. Eastern TimePRINCETON, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business update and reported financial results for the third quarter of 2024. “Since our last update in August, we have been actively e

GlobeNewswire 3 months ago

PDSB
-8.21%
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2024, and provide a clinical program update on Thursday, November 14, 2024, at 8:30 a.

GlobeNewswire 3 months ago

PDSB
-8.21%
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 4 months ago

PDSB
-8.21%
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute at Cytokines 2024PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the rationale and trial design for a st

GlobeNewswire 4 months ago

PDSB
-8.21%
Best Momentum Stocks to Buy for October 15th

ORLA, BABA and PDSB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 15, 2024.

Zacks 4 months ago

BABA

PDSB
-8.21%
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)88% (15/17) of patients had a complete metabolic responseIMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024 PRINCETON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune

GlobeNewswire 5 months ago

PDSB
-8.21%
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3 clinical trial planned to begin this year PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infect

GlobeNewswire 5 months ago

PDSB
-8.21%
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Presentation of data will take place on Saturday, September 14, 2024PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV (formerly PDS0101) in combination w

GlobeNewswire 5 months ago

PDSB
-8.21%
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in

GlobeNewswire 6 months ago

PDSB
-8.21%

Performance Overview

Return	PDSB	S&P 500
YTD	-24.54%	-1.89%
1-Year	-78.87%	+11.88%
3-Year	-75.98%	+37.35%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PDS Biotechnology Corporation (PDSB)

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

PDS Biotechnology: Q3 Earnings Snapshot

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

Best Momentum Stocks to Buy for October 15th

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Performance Overview